The quarter's headline numbers reveal a company struggling with consistency: whilst net sales declined 2.46% year-on-year to ₹4.36 crores, operating margins improved to 14.45% from 12.30% in Q4 FY25. The profit turnaround was significantly aided by ₹0.22 crores in other income, raising questions about the sustainability of core operational performance. The stock has underperformed dramatically, down 29.54% over the past year against the Sensex's 7.43% decline, reflecting investor scepticism about the company's erratic earnings trajectory.
The company's volatile earnings pattern becomes evident when examining the quarterly progression. After posting a loss in Q4 FY25, N G Industries recovered through FY26, but the trajectory has been uneven. The latest quarter's profit of ₹0.69 crores represents the highest quarterly net profit in the recent period, yet the six-month performance tells a sobering story: cumulative profit of ₹1.11 crores for H2 FY26 declined 74.07% compared to the extraordinary ₹9.68 crores reported in H2 FY25, which was inflated by exceptional other income.
Financial Performance: Modest Recovery Masks Structural Concerns
N G Industries' Q4 FY26 financial performance presents a mixed picture of marginal operational improvement overshadowed by revenue stagnation. Net sales of ₹4.36 crores grew a mere 1.63% quarter-on-quarter from ₹4.29 crores in Q3 FY26, whilst declining 2.46% year-on-year from ₹4.47 crores in Q4 FY25. This lacklustre top-line growth reflects the challenges facing the company's healthcare services operations, which include N. G. Medicare & Calcutta Hope Infertility Clinic, N. G. Nursing Home, and N. G. Pharmacy.
Operating profit (PBDIT excluding other income) reached ₹0.63 crores in Q4 FY26, representing a 14.45% margin—an improvement from the 12.30% margin in Q4 FY25 and the highest quarterly operating margin in recent periods. This margin expansion was driven by controlled employee costs of ₹0.66 crores (15.14% of sales) and disciplined expense management. However, the modest absolute operating profit of ₹0.63 crores on a quarterly revenue base of ₹4.36 crores underscores the company's limited scale and pricing power.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | YoY Growth | Operating Margin | Net Profit (₹ Cr) | PAT Margin |
|---|---|---|---|---|---|---|
| Mar'26 | 4.36 | +1.63% | -2.46% | 14.45% | 0.69 | 15.83% |
| Dec'25 | 4.29 | +5.93% | +7.25% | 11.66% | 0.42 | 9.79% |
| Sep'25 | 4.05 | +9.46% | -7.53% | 8.15% | 0.43 | 10.62% |
| Jun'25 | 3.70 | -17.23% | — | 9.19% | 0.19 | 5.14% |
| Mar'25 | 4.47 | +11.75% | — | 12.30% | -2.43 | -54.36% |
| Dec'24 | 4.00 | -8.68% | — | 10.25% | 6.71 | 167.75% |
| Sep'24 | 4.38 | — | — | 10.27% | 2.97 | 67.81% |
The quality of earnings remains questionable due to the significant contribution from other income. In Q4 FY26, other income of ₹0.22 crores represented 31.88% of profit before tax of ₹0.69 crores, highlighting the company's dependence on non-operating sources. This pattern has been consistent: FY25 saw other income of ₹8.00 crores on total revenue of ₹16.00 crores, artificially inflating profitability. The company's core healthcare services operations appear unable to generate sustainable profits at current scale.
A particularly concerning aspect is the zero tax provision in Q4 FY26 despite reporting profit before tax of ₹0.69 crores. This compares to tax rates of 28.81% in Q3 FY26 and 29.63% in Q2 FY26, raising questions about the nature of income recognition or utilisation of carried-forward losses. The company's five-year average tax ratio stands at just 1.46%, far below normal corporate tax rates, suggesting persistent loss-making operations in the past.
Critical Earnings Quality Concern
N G Industries' profitability is heavily reliant on volatile other income rather than core healthcare operations. In Q4 FY26, other income contributed ₹0.22 crores to a net profit of ₹0.69 crores. The company posted extraordinary other income of ₹7.67 crores and ₹3.20 crores in Dec'24 and Sep'24 respectively, which has now normalised, exposing the weakness of underlying operations. This dependence on non-operating income undermines earnings sustainability and investor confidence.
Operational Challenges: Scale Limitations and Profitability Pressures
N G Industries operates in the competitive healthcare services sector with three primary divisions, but the company's micro-cap status (₹39.00 crores market capitalisation) reflects its limited operational scale. The company's quarterly revenue has remained range-bound between ₹3.70 crores and ₹4.47 crores over the past seven quarters, indicating stagnant business growth. For a healthcare provider offering medical services, infertility treatment, nursing home facilities, and pharmacy operations, this revenue base suggests either limited patient volumes or constrained pricing power.
The company's return metrics paint a concerning picture of capital efficiency. Return on equity (ROE) averaged 16.25% over the five-year period, which appears respectable on the surface. However, the latest ROE stands at -3.55%, reflecting the loss-making Q4 FY25 period that dragged down trailing twelve-month profitability. More troubling is the return on capital employed (ROCE) of just 2.64% as of the latest period, with a five-year average of 5.05%—far below the cost of capital and indicative of poor asset utilisation.
The balance sheet reveals a debt-free company with minimal financial leverage, which is one of the few bright spots. As of March 2025, shareholder funds stood at ₹38.52 crores with zero long-term debt, resulting in a net cash position (average net debt to equity of -0.03). Current liabilities of ₹2.44 crores are modest and manageable. However, the company's investments of ₹31.73 crores (82.35% of shareholder funds) suggest significant capital is locked in non-operating assets rather than being deployed in growth initiatives.
Capital Allocation Concerns
N G Industries holds ₹31.73 crores in investments against shareholder funds of ₹38.52 crores—representing 82.35% of equity deployed outside core healthcare operations. Fixed assets total just ₹5.64 crores, indicating minimal reinvestment in medical infrastructure or facility expansion. This capital allocation suggests management prioritises treasury management over operational growth, which may explain the stagnant revenue trajectory and limited scale expansion over the years.
The company's sales to capital employed ratio averaged just 0.59x over five years, indicating inefficient asset utilisation. For every rupee of capital employed, N G Industries generates merely 59 paise of revenue—a concerning metric for a services business that should theoretically achieve higher asset turns. This inefficiency, combined with weak ROCE, suggests the company struggles to deploy capital productively in its healthcare services operations.
Healthcare Services Sector: Headwinds and Competitive Pressures
The broader healthcare services sector in India has delivered strong returns, with the Healthcare Services index generating 19.60% returns over the past year. N G Industries' 29.54% decline over the same period represents a stark underperformance of 49.14 percentage points, highlighting company-specific challenges rather than sector-wide issues. The micro-cap's struggles contrast sharply with the growth trajectory of larger, more established healthcare providers.
N G Industries operates in specialised niches—infertility treatment through Calcutta Hope Infertility Clinic and general medical services through N. G. Medicare and nursing home facilities. Whilst these segments offer growth potential given India's rising healthcare needs and increasing awareness of fertility treatments, the company's inability to scale operations suggests competitive disadvantages. Larger hospital chains and specialised fertility centres with superior infrastructure, medical expertise, and brand recognition likely capture the bulk of market growth.
The company's research and development laboratory for embryology and diagnostics represents a potential differentiator, but the financial results provide no evidence of this translating into competitive advantage or revenue growth. The approval for cashless services under various health insurance schemes is a positive enabler, yet quarterly revenue trends show no acceleration from this access to insured patients. The disconnect between operational capabilities and financial performance suggests execution challenges or market positioning weaknesses.
Peer Comparison: Valuation Disconnect and Competitive Disadvantage
Comparing N G Industries to peer healthcare services providers reveals significant valuation and operational gaps. The company's loss-making trailing twelve-month performance results in an undefined P/E ratio, whilst peers trade at multiples ranging from 9.95x to 127.60x. This valuation disconnect reflects investor recognition that N G Industries lacks the profitability consistency and growth visibility of competitors.
| Company | Market Cap (₹ Cr) | P/E (TTM) | Price to Book | Dividend Yield |
|---|---|---|---|---|
| N G Industries | 39.00 | NA (Loss Making) | 1.06 | 2.83% |
| Royal Sense | — | 9.95 | 1.87 | — |
| Shree Pacetronix | — | 17.54 | 3.09 | — |
| Bandaram Pharma | — | 127.60 | 3.89 | 0.05% |
| Amkay Products | — | 15.81 | 2.03 | — |
| KMS Medisurgi | — | 99.60 | 5.27 | — |
N G Industries' price-to-book ratio of 1.06x appears reasonable compared to peers trading between 1.87x and 5.27x, but this modest valuation reflects the company's poor return on equity rather than representing an attractive entry point. With the latest ROE at -3.55% and five-year average ROE of 16.25%, the company generates insufficient returns to justify even its current book value multiple. In contrast, peers like Royal Sense (21.78% ROE) and Amkay Products (20.09% ROE) command premium valuations due to superior capital efficiency.
The company's dividend yield of 2.83% (based on ₹3.50 per share dividend declared in September 2025) provides some income support, but this appears unsustainable given the erratic earnings pattern. The dividend payout ratio is undefined in the data, but paying ₹3.50 per share against quarterly profits ranging from ₹0.19 crores to ₹0.69 crores suggests management is distributing capital despite weak operational performance—a questionable capital allocation decision.
Valuation Analysis: Expensive Despite Micro-Cap Status
N G Industries' valuation metrics present a paradox: despite being a struggling micro-cap with inconsistent earnings, the stock trades at expensive multiples on certain parameters. The EV/EBITDA ratio of 23.27x significantly exceeds reasonable valuations for a low-growth, low-margin healthcare services provider. Similarly, the EV/EBIT multiple of 36.39x reflects an unjustified premium given the company's operational challenges and scale limitations.
The company's enterprise value to sales ratio of 2.42x appears elevated for a business generating single-digit operating margins and declining revenue. For context, this multiple typically applies to high-growth technology or pharmaceutical companies with strong margin profiles, not to a stagnant healthcare services provider with ₹16.00 crores in annual revenue. The valuation disconnect suggests the market has not fully adjusted to the deteriorating fundamentals, or that the micro-cap's limited liquidity distorts pricing.
The proprietary Mojo scoring system assigns N G Industries a "VERY ATTRACTIVE" valuation grade, which appears contradictory to the expensive multiples. However, this assessment likely reflects the price-to-book ratio of 1.06x and the recent 30.59% decline from 52-week highs of ₹171.45, rather than earnings-based valuation metrics. The stock's 29.54% one-year decline has compressed valuations, but the fundamental deterioration justifies the price correction rather than creating an attractive entry opportunity.
Shareholding Pattern: Stable Promoter Control, Zero Institutional Interest
N G Industries' shareholding structure reveals stable promoter control but complete absence of institutional validation. Promoter holding has remained unchanged at 74.50% across the past five quarters through March 2026, with the balance 25.50% held by non-institutional investors. Key promoters include Ritu Goenka (20.89%), Varsha Goenka (17.91%), Neha Goenka (17.91%), and Rajesh Goenka (17.79%), representing family ownership concentration.
| Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | Mar'25 |
|---|---|---|---|---|---|
| Promoter | 74.50% | 74.50% | 74.50% | 74.50% | 74.50% |
| FII | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Mutual Funds | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Insurance | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other DII | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-Institutional | 25.50% | 25.50% | 25.50% | 25.50% | 25.50% |
The complete absence of foreign institutional investors (FIIs), mutual funds, insurance companies, and other domestic institutional investors (DIIs) represents a significant red flag. Institutional investors conduct rigorous due diligence and typically avoid companies with governance concerns, limited growth visibility, or operational challenges. The zero institutional holding indicates professional investors see insufficient merit in N G Industries' investment proposition, despite the micro-cap's dividend yield and debt-free balance sheet.
The static shareholding pattern over five quarters suggests neither promoters nor public shareholders are adjusting positions, indicating low conviction on both sides. Promoters maintaining 74.50% holding without increasing stake despite the 29.54% price decline over the past year suggests limited confidence in near-term recovery. Simultaneously, the absence of institutional buying during the correction confirms professional investors remain uninterested even at compressed valuations.
Stock Performance: Severe Underperformance Across Timeframes
N G Industries' stock performance has been dismal across virtually all timeframes, with the company destroying shareholder value relative to broader market indices. The stock declined 29.54% over the past year compared to the Sensex's 7.43% fall, generating negative alpha of 22.11 percentage points. Year-to-date performance through May 2026 shows a 20.51% decline against the Sensex's 11.33% drop, underperforming by 9.18 percentage points.
| Period | N G Industries Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +1.80% | +0.20% | +1.60% |
| 1 Month | -14.45% | -2.49% | -11.96% |
| 3 Month | -19.95% | -7.04% | -12.91% |
| 6 Month | -5.10% | -11.83% | +6.73% |
| YTD | -20.51% | -11.33% | -9.18% |
| 1 Year | -29.54% | -7.43% | -22.11% |
| 2 Years | -29.12% | +1.43% | -30.55% |
| 3 Years | +35.41% | +20.24% | +15.17% |
The technical picture is uniformly negative. N G Industries trades below all key moving averages: 5-day MA (₹117.05), 20-day MA (₹124.35), 50-day MA (₹127.16), 100-day MA (₹133.51), and 200-day MA (₹139.32). This bearish alignment indicates sustained selling pressure and absence of support levels. The stock changed to a "BEARISH" technical trend on May 18, 2026, at ₹115.95, having oscillated between bearish and mildly bearish classifications throughout late 2025 and early 2026.
The stock's high beta of 1.50 (adjusted) classifies it as significantly more volatile than the broader market, amplifying downside risk during market corrections. With 56.76% annualised volatility over the past year, N G Industries falls into the "HIGH RISK LOW RETURN" category—the worst possible risk-return profile for investors. The risk-adjusted return of -0.52 compares unfavourably to the Sensex's -0.57, indicating the stock provides no compensation for its elevated risk.
Trading volumes remain anaemic, with just 710 shares changing hands on May 29, 2026, highlighting severe liquidity constraints. The one-month delivery volume surge of 366.13% suggests some accumulation activity, but the low absolute volumes (1,370 shares average over the trailing month) indicate this represents minimal capital deployment rather than institutional interest. The combination of high volatility, low liquidity, and negative price momentum creates a treacherous environment for investors.
Investment Thesis: Multiple Red Flags Outweigh Limited Positives
The proprietary Mojo scoring system assigns N G Industries an overall score of 26 out of 100, placing it firmly in "STRONG SELL" territory (0-30 range). This assessment reflects the convergence of weak fundamentals, deteriorating technicals, and unfavourable valuation despite the recent price correction. The four-pillar Mojo framework reveals systemic weaknesses across critical investment parameters.
Near-Term Drivers: MIXED – The quarterly financial trend is classified as "FLAT" following Q4 FY26 results, indicating neither strong momentum nor severe deterioration. However, the bearish technical trend suggests market participants anticipate further weakness. The combination of stagnant operational performance and negative price action provides no catalyst for near-term recovery.
Quality: BELOW AVERAGE – N G Industries qualifies as a "Below Average quality company based on long-term financial performance." The 5.93% five-year sales growth and 11.84% EBIT growth represent weak expansion for a healthcare services provider. Average ROCE of 5.05% falls far short of acceptable return thresholds, whilst the weak EBIT to interest coverage (1.38x average) indicates limited earnings cushion despite negligible debt.
Valuation: VERY EXPENSIVE – Despite the "VERY ATTRACTIVE" valuation grade assigned by the Mojo system, earnings-based multiples like EV/EBITDA (23.27x) and EV/EBIT (36.39x) indicate expensive pricing. The loss-making trailing twelve-month performance eliminates meaningful P/E comparison, whilst the 1.06x price-to-book ratio fails to compensate for negative ROE.
Overall Assessment: MIXED – The convergence of flat financial trends, below-average quality, bearish technicals, and expensive valuations creates an unfavourable risk-reward proposition. The absence of institutional investors, zero revenue growth visibility, and persistent earnings volatility reinforce the cautious stance.
KEY STRENGTHS ✓
- Debt-Free Balance Sheet: Zero long-term debt with net cash position provides financial stability and flexibility.
- Stable Promoter Holding: 74.50% promoter stake maintained consistently with no pledging indicates ownership commitment.
- Margin Improvement: Q4 FY26 operating margin of 14.45% represents highest level in recent quarters, showing operational discipline.
- Dividend Yield: 2.83% dividend yield provides some income support in current market environment.
- Specialised Services: Infertility treatment and research laboratory offer niche positioning in growing healthcare segment.
- Insurance Approvals: Cashless service approvals under various health insurance schemes enable broader patient access.
KEY CONCERNS âš
- Revenue Stagnation: Quarterly sales range-bound between ₹3.70-₹4.47 crores with no growth trajectory visible.
- Earnings Volatility: Erratic quarterly profits ranging from losses of ₹2.43 crores to gains of ₹6.71 crores undermine predictability.
- Other Income Dependence: Profits heavily reliant on volatile other income rather than sustainable operational performance.
- Weak Returns: Latest ROCE of 2.64% and ROE of -3.55% indicate poor capital efficiency and value destruction.
- Zero Institutional Interest: Complete absence of FII, mutual fund, and insurance holdings signals professional investor avoidance.
- Limited Scale: ₹39.00 crores market cap and ₹16.00 crores annual revenue indicate micro-cap constraints and limited competitive positioning.
- High Volatility: 56.76% annualised volatility with 1.50 beta creates elevated downside risk during market corrections.
Outlook: What to Watch
N G Industries faces a critical juncture where management must demonstrate operational turnaround capability or risk continued value erosion. The company's micro-cap status and limited institutional following mean any positive developments could generate disproportionate returns, but the base case scenario remains challenging given persistent structural weaknesses.
POSITIVE CATALYSTS
- Revenue Acceleration: Sustained quarterly sales growth above 10% for three consecutive quarters demonstrating market traction.
- Margin Sustainability: Operating margins consistently above 14% without reliance on other income showing core business strength.
- Capacity Expansion: Investment in medical infrastructure or facility additions signalling growth ambitions and capital deployment.
- Institutional Entry: Any mutual fund or insurance company taking positions would validate investment thesis and improve liquidity.
RED FLAGS
- Continued Revenue Decline: Further QoQ or YoY sales contraction indicating market share loss or competitive pressures.
- Return to Losses: Quarterly net losses resuming would confirm inability to achieve sustainable profitability at current scale.
- Promoter Stake Reduction: Any decrease in 74.50% promoter holding would signal reduced ownership confidence.
- Working Capital Deterioration: Increase in current liabilities or decrease in current assets straining liquidity position.
- Dividend Suspension: Elimination of ₹3.50 per share dividend would remove key income support for shareholders.
The Verdict: Avoid This Struggling Micro-Cap
Score: 26/100
For Fresh Investors: Avoid initiating positions in N G Industries. The company's erratic earnings pattern, revenue stagnation, dependence on other income, and complete absence of institutional validation create an unfavourable risk-reward profile. The micro-cap's limited liquidity (710 shares daily volume) and high volatility (56.76%) amplify downside risk. Whilst the debt-free balance sheet provides some cushion, the weak return on capital (2.64% ROCE) and negative trailing ROE (-3.55%) indicate persistent value destruction. The bearish technical trend and trading below all moving averages suggest further downside potential. Better opportunities exist in the healthcare services sector with established players demonstrating consistent growth and profitability.
For Existing Holders: Consider exiting positions on any relief rallies. The Q4 FY26 profit turnaround to ₹0.69 crores appears unsustainable given the company's historical volatility and other income dependence. The 29.54% one-year decline reflects justified market scepticism about management's ability to scale operations and generate consistent returns. The absence of institutional interest and flat financial trend classification suggest limited near-term catalysts for recovery. Whilst the 2.83% dividend yield provides some income, the capital erosion risk outweighs this benefit. Holders should reassess whether the capital can be better deployed in higher-quality healthcare services companies with proven growth trajectories and institutional backing. Only long-term investors with high risk tolerance and conviction in management's turnaround capabilities should consider holding through the current challenges.
Fair Value Estimate: ₹95-105 (20% downside risk from current ₹119.00), based on 1.0x book value and adjusting for negative ROE and operational challenges.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
âš ï¸ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance does not guarantee future results. The author and publisher are not responsible for any investment losses incurred based on the information presented in this article.
